SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b).
(Amendment No.__)*
LYNX THERAPEUTICS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
551812 30 8
--------------------------------------------------------------------------------
(CUSIP Number)
April 14, 2004
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act, but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 5
---------------------- ----------------------
CUSIP No. 551812 30 8 13G Page 2---of---5 Pages
---------------------- ----------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE
PERSONS (Entities Only)
Manteia SA
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions) (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
540,058
SHARES --------------------------------------------------------------
6 SHARED VOTING POWER
BENEFICIALLY N/A
--------------------------------------------------------------
OWNED BY EACH 7 SOLE DISPOSITIVE POWER
540,058
REPORTING --------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
PERSON WITH N/A
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
540,058
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (See Instructions) [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.2%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
CO
--------------------------------------------------------------------------------
---------------------- ----------------------
CUSIP No. 551812 30 8 13G Page 3---of---5 Pages
---------------------- ----------------------
ITEM 1(a). NAME OF ISSUER:
Lynx Therapeutics, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
25861 Industrial Boulevard
Hayward, CA 94545
ITEM 2(a). NAME OF PERSON FILING:
Manteia SA
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Manteia SA
Zone Industrielle
1267 Coinsins
Switzerland
ITEM 2(c). CITIZENSHIP:
A stock company organized under the laws of Switzerland.
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, par value $0.01 per share
ITEM 2(e). CUSIP NUMBER:
551812308
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b), OR 13D-2(b)
OR (c), CHECK WHETHER THE PERSON FILING IS A: N/A
Not applicable.
ITEM 4. OWNERSHIP.
The ownership percentage set forth below is based on 7,527,538 shares of
common stock outstanding as of April 14, 2004.
(a) Amount beneficially owned: 540,058
(b) Percent of class: 7.2%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 540,058
(ii) Shared power to vote or to direct the vote: N/A
(iii) Sole power to dispose or to direct the disposition of: 540,058
---------------------- ----------------------
CUSIP No. 551812 30 8 13G Page 4---of---5 Pages
---------------------- ----------------------
(iv) Shared power to dispose or to direct the disposition of: N/A
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
OR CONTROL PERSON.
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
ITEM 10. CERTIFICATIONS.
By signing below, I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
---------------------- ----------------------
CUSIP No. 551812 30 8 13G Page 5---of---5 Pages
---------------------- ----------------------
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: April 14, 2004
Manteia SA
/s/ Francois Naef
--------------------------------------
By: Francois Naef
Title: Director